If you are interested in any of the following business opportunities, please send an email to office@zangani.com, along with the appropriate reference number.

1) Biopharmaceuticals

Specializes in the discovery, development, production and commercialization of innovative biopharmaceuticals, diagnostics and biogenerics. Type of Cooperation: Development of new projects (r&dt), technology transfer or production license, identification of new customers, direct investments, joint creation of an enterprise or consortium, development of new products. Business proposal: Seeking strategic and financial partners for the following: Spinning off its biogenerics activity, Partnering on the development of biosimilar products for the European/US markets, Spinning off a cancer diagnostics company, Development of novel (patented) anti-cancer/inflammation monoclonal antibody, Investment in the company.

2) Biotechnology

A leader company in automatic DNA sequencing, the production and manipulation of DNA/RNA in all Italy and next target is to sequence the whole genome on higher organisms in a very short time (one week). Our project involves the production of slides (chips) for the analysis expression of microRNA (miRs) in eukaryotic cells.

3) Biotechnology

Arginorfina is a new molecule with analgesic and anxiolytic action lacking of opiate drug side effects derivative of dermorphine after aimed and suitable amino-acid modifications arginorfina. It has stronger potency and analgesic duration than morphine both by intratecal administration and by periferic intravenous or intradermic administration.

4) Biotechnology

A privately held biopharmaceutical company focused on discovery and development of novel small molecule therapeutics for oncology and cytoprotection. The company’s proprietary medicinal chemistry library and cell-based screening platform have yielded many promising drug candidates, including novel bcr-abl directed inhibitors that are active against all known Gleevec®-resistant mutations of this enzyme. This novel antileukemic compound is currently in the pre-clinical stage.

5) Biotechnology

A life sciences company developing products to benefit the immune system. The Company’s LAIT™ Protein is a natural and biologically active milk protein fraction, and the only known breast milk protein to directly stimulate B cell growth and antibody production. The company is launching LAIT™ Protein as an innovative ingredient for functional foods and supplements, with a product pipeline of applications for infant formula, topical products and vaccine adjuvants.

6) Biotechnology

They discovered that Exosomes released from tumor cells differ significantly from those released from normal cells in composition and in proteins’ load. They developed a non invasive method to be used in epidemiological screening for an early diagnosis of different tumor’s histology as well as diagnosis and follow up of tumor patients.

7) Biotechnology

A drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies. The company has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling the company (and its strategic partners) to advance novel drug therapeutics and diagnostics.

8) Biotechnology - New Technology - New Meterials

An international initiative gathering public and private research institutions and aimed at setting up innovative technologies and procedures for tissue engineering. A multidisciplinary approach makes them a platform of excellence to promote the most innovative solutions in regenerative mediciment.

9) Life Sciences Services

Contract Research Organisation principally oriented in managing clinical studies in full compliance with standards of Good Clinical Practice (ICH). Being a full spectrum CRO, can be an ideal business partner for all your clinical needs in developing any new product. DR provides with expertise in all areas of Clinical Research a complete range of Services for international and national management of clinical trials in Western and Eastern Europe, USA, Canada, India and Australia.

10) New Materials and New Technology

Current first-line breast cancer detection strategy still depends essentially on clinical examination and mammography. Owing to infrared imaging’s unique ability to image the metabolic aspects of the breast, extremely early warning signals (up to 10 years before any other detection method) have been observed in long-term studies. Our Artificial Intelligence algorithm is able to help the interpretation of Infrared noisy images to successfully highlight anomalous dynamic behaviors associated with pre-cancer formations.

11) New Materials and New Technology

Presenting an instrument specifically studied and created for coagulation treatment preliminary to the act of resection, for the purpose of reducing and/or eliminating bleeding during and after surgical treatment of parenchymatous organs.

12) New Technology

A polifunctional fixation system in the modern techniques of percutaneous synthesis in the fractures, as well as a modern and efficient surgical instrumentation and equipment called “Miniopen wire instruments”. Percutaneous Nail System - PNS is a new system of percutaneous nailing in old patients with proximal femur fractures.

13) New Technology

A company deep active in the field of industrial design, prototyping and engineering of product, related to the disability and ergonomic sectors. Our top product is Comfortbody, an innovative underwear for pregnant women which is able to minimise the negative effects on the vertebral column due to the weight of foetus in pregnant women. The functionality of this body has been proved by medical tests.

14) New Technology

Wireless network for human biometric monitoring which can operate in low rate (250 kbps) Wireless Personal Area Network. The power consumption of such network allows the network to operate for years before the need of change the battery. We can take under control breath, cardiac pulse, temperature, ECG, and directly fill in a digital folder in a computer which can be in the same room or somewhere else connected in a wide area network.

15) New Technology

They are looking for scientific, technological, business and execution excellence. They are attracted to markets of significant size. But above all, they back passionate entrepreneurs who want to change the world with their tiny technology enabled products. Proprietary, well protected and highly differentiated technology is a prerequisite. But above all, they are eager to invest in companies with market centric strategies that seek to define and dominate large product categories. type of cooperation: direct investments, joint creation of an enterprise or consortium, venture capital.

16) Pharmaceuticals

A public biopharmaceutical company with over 13 years operation in China. It is fully integrated with solid infrastructures in drug development, clinical development , regulatory , manufacturing, sales & marketing in China. The company focuses on several areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology & others. It has more than 15 products under different development stages stemming from internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies. Sigma Tau Group, the leading international pharmaceutical company based in Rome (Italy), is a strategic shareholder. Sigma Tau’s ongoing R&D activities and commercial know-how will result in creating significant business synergies for the company.

17) Pharmaceuticals

An emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by either medical professionals or consumers, the company is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care. The strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide. The Company's technology portfolio, leveraging 15 patents and licenses based on core intellectual property related to lateral flow techniques that rapidly provide medical information directly to the healthcare provider or patient.

18) Pharmaceuticals

Provides an array of strategic services to get the managed care knowledge and assessment you need to turn high science into highly successful investments. Our team is comprised of a group of senior managers with more than 20 years of expertise in defining reimbursement strategy and business planning. We are uniquely qualified to provide information and services for emerging medical innovations and the biocapital resources that fund them. Whether you are an investor needing to understand the reimbursement ramifications surrounding the product you are investing in, or an executive who needs to ensure your managed market success, we can help. Investing in or managing a life science or biotech business is not just about the science, it is also about the business and the impact reimbursement issues can have on commercial success.

19) Pharmaceuticals - Biotechnology

The company has developed and patented some products to: - prevent and cure hypoferremia and anaemia in pregnant women or in subjects suffering from iron deficiency anaemia; - cure microbial and viral infections and relative inflammations; - prevent and cure gingivitis and periodontitis

20) Pharmachology

Developing a new platform of pharmaceutical targets, relevant for the development of new therapeutical approaches to severe neurodegenerative disorders such as Alzheimer’s disease. This target platform is based on a new mechanism discovered and links deficits or defects in the signalling of NGF to the pathological activation of the amyloidogenic cascade. Based on this mechanism, new cell and animal models for the screening of compounds against these targets are being developed.

21) Security Technology

Designs, manufactures and markets loss prevention systems utilizing the latest digital surveillance technology. Our customers include small businesses, mid- and large-sized corporations and government entities. We propose to form a formal Joint-Venture to develop a Pharma-specific management program to utilize remote managed video surveillance to improve manufacturing and distribution efficiency, increase productivity and reduce liability and shrinkage in pharmaceutical and similar regulated applications.